Gabapentin Capsule
Product Images NDC 87441-035

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 87441-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 300 mg (8744103501 Gabapentin 300 mg)

Gabapentin 300 mg capsules label marked Rx only, repackaged by Unit Dose Solutions, Inc. The label includes dosing information, pharmacist dispensing instructions, storage conditions at 20° to 25°C, and distributor information from Tuckahoe Enterprises, LLC. The label shows the product NDC as 87441-035-01.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula illustrating the calculation of creatinine clearance (CLCr) incorporating age, weight, serum creatinine level, and a correction factor for female patients.*

FDA Label Image

Structure (Gabapentin Fig 5)

Chemical structure of gabapentin showing a cyclohexane ring attached to two substituents: a CH2NH2 group and a CH2CO2H group.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over an 8-week period, comparing placebo and gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to 8, with annotations for a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain scores over 7 weeks. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis displays mean pain scores from 0 to 10. Three groups are compared: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, with pain scores decreasing more in the Gabapentin groups than placebo over time.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. Study 1 compares placebo (12%) to Gabapentin 3600 mg (29%), while Study 2 compares placebo (14%) to Gabapentin 1800 mg (32%) and Gabapentin 2400 mg (34%). Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A scatter plot comparing three different studies labeled 'STUDY a,' 'STUDY b,' and 'STUDY c,' showing percentage difference on the y-axis versus daily dose in milligrams on the x-axis. The graph plots data points for daily doses of approximately 600 mg, 900 mg, 1200 mg, and 1800 mg with varying percent differences up to 22%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.